Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Nutr Metab Cardiovasc Dis. 2010 May 31;21(10):776–782. doi: 10.1016/j.numecd.2010.02.003

Table 1.

Baseline general characteristics, cardiovascular risk factors and inflammatory markers of InCHIANTI Study participants according to the presence vs absence of carotid artery plaques at baseline (left side) and of new carotid artery plaques at three-year follow-up (right side).

Carotid artery plaques at baseline
(n. 1168) (*)
New carotid artery plaques at follow-up
(n. 486) (†)


Presence Absence Presence Absence




n. 538 (46.1%) n. 630 p (‡) n. 195 (40.1%) n. 291 p (‡)






General characteristics
Age (years) (mean ± SD) 75.5 ± 8.3 61.7 ± 17.2 < 0.001 71.2 ± 7.2 56.6 ± 16.9 < 0.001
Sex (% females) 49.6 60.0 < 0.001 59.5 58.4 0.576
Chronic respiratory, urinary tract and dental Infections (%) 49.7 33.4 0.316 43.7 24.7 0.260
Use of statins and/or antiinflammatory drugs (%) 13.0 8.9 0.451 11.8 7.2 0.987
Cardiovascular risk factors
Family medical history of atherosclerosis (%) 51.0 43.5 0.011 55.9 37.1 0.024
Physical activity level previous year (score 0-4, 4 best) (mean ± SD) 1.29 ± 0.89 1.51 ± 0.87 0.612 1.35 ± 0.74 1.71 ± 0.86 0.337
BMI (kg/m2) (mean ± SD) 27.5 ± 3.7 27.1 ± 4.4 0.628 27.9 ± 4.2 26.7 ± 4.4 0.891
Pack-years Index (mean ± SD) 15.1 ± 22.1 7.6 ± 14.4 < 0.001 10.5 ± 17.2 5.5 ± 9.9 0.001
Total Cholesterol (mg/dL) (mean ± SD) 219.2 ± 39.4 212.6 ± 40.1 0.173 221.1 ± 36.3 210.1 ± 41.6 0.637
LDL-Cholesterol (mg/dL) (mean ± SD) 138.5 ± 33.7 132.0 ± 35.7 0.138 141.1 ± 32.2 129.8 ± 37.4 0.818
HDL-Cholesterol (mg/dL) (mean ± SD) 54.5 ± 15.1 56.0 ± 14.4 0.687 54.2 ± 12.5 56.9 ± 14.8 0.269
Triglycerides (mg/dL) (mean ± SD) 130.6 ± 72.4 123.3 ± 82.6 0.795 128.5 ± 65.9 117.2 ± 69.4 0.416
Diabetes (%) 13.5 6.3 0.021 9.7 2.6 0.104
Hypertension (%) 77.1 49.2 < 0.001 62.2 36.0 0.780
Metabolic Syndrome (%) 25.6 18.5 0.135 20.8 16.4 0.280
Coronary artery disease (%) 9.5 3.2 0.080 6.6 0.3 0.037
Perpheral artery disease (%) 16.3 4.0 0.001 5.2 1.0 0.094
Inflammatory markers
C-reactive protein high sensitivity (μg/mL) (mean ± SD) (§) 5.89 ± 10.81 3.76 ± 6.56 0.006 4.45 ± 5.30 2.57 ± 3.56 0.005
Interleukin 1-β (pg/mL) (mean ± SD) (§) 0.28 ± 1.34 0.32 ± 1.80 0.342 0.29 ± 1.77 0.29 ± 1.48 0.286
Interleukin 1 receptor antagonist (pg/mL) (mean ± SD) (§) 162.9 ± 124.0 152.6 ± 125.0 0.798 154.4 ± 94.8 143.0 ± 106.6 0.192
Interleukin 6 (pg/mL) (mean ± SD) (§) 2.32 ± 4.41 1.52 ± 1.80 0.516 1.70 ± 1.51 1.21 ± 1.77 0.172
Interleukin 6 soluble receptor (ng/mL) (mean ± SD) (§) 105.0 ± 55.6 99.3 ± 58.6 0.148 102.7 ± 59.7 99.5 ± 61.7 0.341
Tumor necrosis factor α (pg/mL) (mean ± SD) (§) 3.85 ± 6.00 3.02 ± 3.92 0.891 3.22 ± 4.14 2.69 ± 3.55 0.672
(*)

Participants with complete data at baseline.

(†)

Participants free from carotid artery plaques at baseline who received a carotid artery scan at three-year follow-up.

(‡)

From age- and sex-adjusted linear or logistic regressions, as appropriate.

(§)

Variables log-transformed before being entered into regressions due to marked skewness.